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Abstract
Insulin-degrading enzyme (IDE) is a neutral Zn2+ peptidase that degrades short peptides based on substrate conformation,
size and charge. Some of these substrates, including amyloid b (Ab) are capable of self-assembling into cytotoxic oligomers.
Based on IDE recognition mechanism and our previous report of the formation of a stable complex between IDE and intact
Ab in vitro and in vivo, we analyzed the possibility of a chaperone-like function of IDE. A proteolytically inactive recombinant
IDE with Glu111 replaced by Gln (IDEQ) was used. IDEQ blocked the amyloidogenic pathway of Ab yielding non-fibrillar
structures as assessed by electron microscopy. Measurements of the kinetics of Ab aggregation by light scattering showed
that 1) IDEQ effect was promoted by ATP independent of its hydrolysis, 2) end products of Ab-IDEQ co-incubation were
incapable of ‘‘seeding’’ the assembly of monomeric Ab and 3) IDEQ was ineffective in reversing Ab aggregation. Moreover,
Ab aggregates formed in the presence of IDEQ were non-neurotoxic. IDEQ had no conformational effects upon insulin (a
non-amyloidogenic protein under physiological conditions) and did not disturb insulin receptor activation in cultured cells.
Our results suggest that IDE has a chaperone-like activity upon amyloid-forming peptides. It remains to be explored
whether other highly conserved metallopeptidases have a dual protease-chaperone function to prevent the formation of
toxic peptide oligomers from bacteria to mammals.
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Introduction
The formation of amyloid is a process by which disordered
peptides or specific regions of partially unfolded proteins self-
assemble to yield fibrils with a typical morphology, a cross-b
structure and affinity to dyes such as Congo red. A growing
number of proteins capable of forming amyloid are associated with
human pathology, including high prevalence diseases such as type
2 diabetes mellitus (DM2) and dementia. In vitro, amyloid fibril
formation follows a typical nucleation-dependent kinetics [1] that
includes key variables such as critical concentration, nuclei
formation, lag phase, exponential growth and steady state. One
or more pathways may lead to the conversion of monomeric
soluble proteins or peptides into amyloid fibrils [2,3,4]. Alterna-
tively, ‘‘off-pathway’’ oligomeric products relative to amyloid
formation may be formed after the initiation of the self-assembly
process. This has been shown by using compounds that inhibit
amyloid b (Ab) oligomer formation without affecting fibrillogenesis
[5,6].
Recent work has raised the possibility that fibril formation may
be protective to cells by stabilizing non-amyloid cytotoxic
intermediates, as proposed for several neurodegenerative diseases
[7,8,9]. Furthermore, amyloid fibrils may play a physiological role
serving as a scaffold for the fast fibrillization of the Ma protein
within melanosomes [10]. Yet, the existence of cytotoxic oligomers
and protofibrils in vivo implies that at least one pathway (either ‘‘on
or off’’ relative to fibril formation) of proteins/peptides aggrega-
tion is likely a pathological process [9,11,12].
Ab, both in fibrillar and non-fibrillar forms, massively
accumulates in the brain in sporadic and hereditary Alzheimer’s
disease (AD) and amyloid angiopathies [13,14,15]. Ab aggregates
are capable of inducing dysfunction or death on neural, glial and
vascular cells. Moreover, several coding missense mutations within
or around the Ab sequence in its precursor protein, APP, are
associated with familial forms of these diseases [16,17,18,19].
At the subcellular level, Ab generation has been tracked along
the late secretory and endocytic pathways, consistent with the
localization of the so called b and c secretases, major protease
complexes that release Ab peptides from APP [20,21,22]. Under
normal conditions, cells shed soluble Ab species to the extracel-
lular compartment without membrane damage [23], yet the sites
of their initial oligomerization under pathological conditions
remain elusive. Although the bulk of Ab fibrils in the brain seem
to be extracellular, recent studies support that Ab oligomers may
be formed intracellularly [24,25,26]. Since self-assembly of Ab is
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dependent on monomer concentration and time, the overall rates
of its production and removal in a given cellular compartment are
key factors in determining the initiation of the amyloidogenic
pathway(s).
Insulin-degrading enzyme (IDE), neprilysin (NEP) and endo-
thelin-converting enzyme (ECE) are among the major Ab
proteases with physiological relevance, as shown by gene knock-
out and transgenic animal models [27,28,29]. Alternatively, the
aggregation of Ab in vivo may be modulated by its interaction with
molecular chaperones. Studies in cell cultures, transgenic C. elegans
and in vitro biophysical data, support that heat-shock proteins (Hsp)
70–90 and small heat shock proteins (sHsp) with chaperone-like
activity interact with Ab and are capable of reducing fibril
formation [30,31]. In addition to these canonical chaperones, Ab
may interact extracellularly with other proteins with chaperone-
like activity. Three secreted glycoproteins, namely, clusterin,
haptoglobin and a2-macroglobulin (a2M), are known to have
ATP-independent chaperone-like activity in vitro [32,33,34,35,36].
Among these, the highly stable interaction of Ab with clusterin, a
multi-funcional protein, leads to diverse effects, depending on
molar ratios that range from prevention of aggregation to
enhancement of fibril formation. Interestingly, HSPs, sHSPs and
clusterin expression is increased in AD brains and co-localize with
Ab deposits in neuropil and vessels or in surrounding astrocytes,
supporting that they participate in some way in the amyloidogenic
process in vivo [37,38,39,40].
IDE is a highly conserved Zn2+ metallopeptidase ubiquitously
expressed in tissues and at the subcellular level. IDE hydrolyzes
insulin and Ab in vivo [41] as well as short bioactive peptides with
amyloidogenic potential such as glucagon, atrial natriuretic
peptide and amylin (reviewed in [42]). We have recently shown
that natively folded IDE is capable of forming a highly stable
complex (IDE-AbSCx) with Ab in vitro and in vivo. The shortest
competent Ab fragment for IDE-AbSCx formation contained the
central LVFF sequence, which seems to be crucial for amyloid
formation [43,44,45]. Interestingly, this sequence is included in the
Ab segment that acquires b-conformation inside the IDE chamber
close to the active site [46].
In this study we present results supporting that the catalytically
inactive mutant IDEQ drastically modifies the Ab self-assembly
pathway, halts amyloid fibril formation and yields non-toxic
aggregates through a chaperone-like activity.
Results
Native IDEQ is highly efficient in forming a stable
complex with Ab1-42
We first confirmed that there were no structural differences
between purified IDE wild type (IDEwt) and IDEQ, as determined
by static light scattering (SLS) and circular dichroism (CD)
(Figure S1). The loss of enzymatic activity of IDEQ was assessed
by four different methods: 1) The absence of fluorescent signal
increase after co-incubation with the fluorogenic substrate V; 2)
The lack of significant degradation as determined by trichlor-
oacetic acid (TCA) precipitation of 125I-insulin (,1.5% residual
activity); 3) Western blots with anti-Ab and 4) Enzyme-linked
immuno-sorbent assay (ELISA) quantification of monomeric Ab1-
42 that remained measurable after 5 days of incubation with
IDEQ (94.4%), IDEwt (10.4%) and IDEwt with EDTA (88.9%) at
a 1:10 molar ratio (enzyme:Ab) (Figure S2). In a prior work [44]
we showed that co-incubation of Ab1-28 with IDEwt yielded
higher levels of IDE-AbSCx when the protease was inhibited with
EDTA. Thus, we tested if natively folded IDEQ produced a
similar effect. A time-course of IDE-AbSCx formation was
determined by quantifying the immunoreactivity of the
,120 kDa band with anti-Ab by Western blot. Although the
half-times of IDE-AbSCx formation were similar (IDEQ = 32 -
min; IDEwt = 26 min), the yield of IDEQ-AbSCx was ,3 -fold
higher relative to IDEwt (Figure 1). To test whether Ab was
interacting with IDEQ substrate-binding site, as previously shown
for IDEwt [44], competition was performed with insulin. Pre-
incubation with increasing concentrations of insulin decreased the
formation of IDEQ-AbSCx reaching a final value of ,22% of the
maximum formed in the absence of insulin (Figure 1). The fact
that prevention was not complete may be attributed to several
factors including the kd (,8 mM) for insulin dimerization (the size
of an insulin dimer is not compatible with the volume of the IDE
chamber), the non-equilibrium reaction that leads to IDEQ-
AbSCx formation and that binding site may not be fully shared
[44].
Figure 1. Time-course, amount and pH-dependence of the
formation of complexes between Ab1-42 and IDEwt or IDEQ.
(A) Western blots with anti-Ab 6E10 showing the ,120 kDa band
corresponding to IDE-AbSCx (IDE-Ab stable complex) as a function of
the incubation time. Top panel, IDEQ; lower panel, IDEwt. Both PVDF
membranes were developed simultaneously with a STORM 860 scanner.
Below each Western blot, the same membranes stained with Coomassie
blue, show IDEwt or IDEQ loading. (B) Densitometric data from Western
blots for IDEQ (q) and IDEwt (m) were fitted to a single exponential
equation using Graph Pad Prism v.4 software. Points represent the
mean6 SEM from two independent experiments in duplicate. (C) IDEQ-
AbSCx formation is partially competed by pre-incubation for 1 h with
insulin at the indicated molar excess before the addition of Ab1-42.
Data are expressed as the percentage of the remaining Ab-positive
band at ,120 kDa, in arbitrary units, as a function of insulin
concentration. Each point represents the mean 6 SEM of two
independent experiments in duplicate. Inset: a representative Western
blot of IDEQ-AbSCx developed with 6E10. (D) Densitometry of IDEQ-
AbSCx at the indicated range of pH as determined by Western blot with
anti-Ab. Bars represent the mean 6 SEM of three separate experiments.
Inset: top, representative Western blot with anti-Ab of IDEQ-AbSCx;
bottom, Coomassie blue of IDEQ loaded in each lane. In panels (A), (C)
and (D), IDEwt or IDEQ-AbSCxs are indicated by arrowheads.
doi:10.1371/journal.pone.0059113.g001
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IDEQ has no effect upon insulin conformation and its
activity on cultured cells
Although insulin does not aggregate under physiological
conditions and low concentrations, it has a high affinity for IDE
and undergoes partial unfolding inside the IDE chamber before
hydrolysis [47]. Having shown that IDEQ was natively folded and
had minimal residual activity, we tested its possible effect on
insulin conformation or aggregation. To address this question, two
experiments were performed. Firstly, insulin was incubated alone
or with IDEQ at 1:100 (enzyme:insulin) for 24 h and secondary
structure determined by CD. Signal intensities were similar and no
differences were seen in the two a-helix minima of insulin with or
without IDEQ at dead time and after 24 h of incubation (Figure 2).
Secondly, human astrocytic U-87 cells were treated with insulin
with or without pre-incubation with IDEQ. The activation of
insulin receptor was assessed by quantifying Akt phosphorylation.
Insulin pre-incubated with IDEwt was used as a positive control
for the loss of insulin activity due to hydrolysis. Insulin treatment
increased phospho-Akt levels relative to total Akt. Pre-incubation
of insulin with IDEQ did not result in a significant loss of hormone
activity, while pre-incubation with IDEwt abolished insulin
receptor activation (Figure 2). When cells were previously treated
with wortmannin, an inhibitor of PI3K, the increase in Akt
phosphorylation was abrogated, indicating the specificity of insulin
pathway activation in the insulin-IDEQ experiment. These results
support that IDEQ, despite binding insulin, does not induce a
conformational change on the hormone or promotes its aggrega-
tion.
Inverse relationship between hydrolysis and IDE-AbSCx
formation as a function of pH
The physical association between IDE and Ab in vivo seems to
be ubiquitous, including intracellular organelles with acidic pH
[48,49]. Therefore, we tested the effect of a range of pH in the
formation of IDE-AbSCx. The activity of IDEwt was drastically
reduced in vitro below pH 6 while the formation of IDEwt-AbSCx
increased from low levels at neutral pH reaching a maximum at
pH 5.5, likely related to reduced degradation of Ab (Figure S3).
Instead, IDEQ was capable of forming comparable amounts of
IDE-AbSCx across the range of pH studied, as shown in Figure 1.
These and our previously reported results prompted us to explore
a functional significance of the stable interaction between IDE and
Ab unrelated to peptide hydrolysis.
IDEQ reduces the size of Ab aggregates
The effect of IDEQ upon Ab self-assembly was first studied by
dynamic light scattering (DLS), which allows a rough estimate of
the size of aggregates in solution. Ab1-42 showed species with
increasing hydrodynamic diameter (DH) and intensity of scattered
light with peaks around 1000 nm after 6.5 days of incubation
(Figure 3). Although the total amount of IDE in the brain is likely
much higher than monomeric Ab [50,51], we used IDEQ at
substoichiometry to minimize non-specific hydrophobic interac-
tions in vitro. Ab1-42 incubated in the presence of IDEQ at 1:10
molar ratio (enzyme: Ab) resulted in the detection of two distinct
populations: one around 10–13 nm, as expected for IDEQ dimers,
and a second population with a peak around 150 nm. Notably,
only two discrete populations with DH of 150 and 400 nm were
seen at the end of incubation, as opposed to Ab1-42 alone
(Figure 3). Similar results were obtained using the highly
amyloidogenic ‘‘Dutch’’ variant of Ab peptide 1–28 in which
Glu is replaced by Gln at position 22 (Ab28Q) (not shown).
IDEQ abolishes the formation of Ab fibrils
To determine the morphology and size of the aggregates
detected by DLS, samples were analyzed by transmission electron
microscopy (TEM). After 6.5 days of incubation, Ab1-42 (Figure 3)
and Ab28Q (Figure S4) formed typical amyloid fibrils. The effect
of co-incubation with IDEQ at 1:10 (enzyme: Ab molar ratio) was
remarkable, with a complete absence of amyloid fibril formation
by Ab1-42 or Ab28Q. In the presence of IDEQ, much smaller
structures were seen. These ranged from thin, short rods or
protofibrils to coalescent annular structures with a diameter of
,5 nm. Similar structures were seen when IDEQ was incubated
alone, although the tendency to form large aggregates was higher
in the Ab-containing samples (Figure 3). When IDEwt inhibited
with EDTA was incubated with Ab1-42, non-fibrilar products
were seen, reinforcing that blockage of amyloid formation was
unrelated to proteolysis (Figure 3). To test if the lack of amyloid
formation by Ab in the presence of IDEQ was due to a retardation
of the fibrillization pathway, samples were co-incubated for
30 days. Amyloid fibrils with the typical features were observed
with Ab1-42 alone. In contrast, only small aggregates were found
in the presence of IDEQ (Figure 3). Typical amyloid fibrils were
formed by Ab28Q in the presence of bovine serum albumin (BSA)
at the same molar ratio (Figure S4), indicating a specific effect of
IDEQ rather than a non-specific, hydrophobic peptide-protein
interaction. Overall, DLS and TEM results indicate that in the
presence of IDEQ at sub-stoichiometry, Ab forms small aggregates
that lack the morphological features of amyloid fibrils. In addition,
by using the shorter Ab1-28Q, we showed that the hydrophobic
transmembrane C-terminal region of Ab was not necessary for the
Figure 2. IDEQ does not modify insulin conformation. (A)
Circular dichroism (CD) spectra of 10 mM insulin (ins.) in working buffer
(solid black line), insulin with IDEQ at 1:100 molar ratio, enzyme:insulin
(solid gray line) and IDEQ alone (dotted line) with no prior incubation.
(B) Same samples as in panel (A) after incubation for 24 h at 25uC.
Insulin alone (solid black line), insulin with IDEQ (solid gray line) and
IDEQ alone (dotted line). (C) Western blot with anti-phospho-Akt and
anti-total Akt of U-87 cell lysates. Cells were exposed for 30 min with
insulin alone, insulin previously co-incubated with IDEwt or IDEQ, as
indicated. Wortmannin (wort) was incubated at 10 nM for 30 min
before treatments.
doi:10.1371/journal.pone.0059113.g002
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underlying peptide-enzyme interaction that halted amyloid
formation.
Kinetics of Ab aggregation in the presence of IDEQ and
effect of ATP
To further characterize the effect of IDEQ on Ab1-42 self-
assembly, the kinetics of aggregation were followed by scattering at
340 nm. Ab1-42 self-assembly showed an initial lag phase of
,12 h, followed by exponential growth of 24–36 h until a steady
state was reached after 48–72 h (the shorter periods of time for
these phases as compared with the rest of the experimental
conditions was due to the repeated agitation every 30 min, as
described in Materials and Methods). Typical amyloid fibrils were
obtained at steady state, as assessed by TEM (Figure 4). At a molar
ratio of 1:10 (enzyme: Ab), IDEQ slowed the rate of aggregation
and the scattered intensity. This effect was concentration-
dependent and it could still be observed at a substoichiometry
(IDEQ: Ab) of 1:200. Interestingly, co-incubation with ATP,
which binds IDE and modulates its conformation and catalytic
activity upon short substrates [52,53], showed an increase in the
anti-aggregation effect (Figure 4). Such enhancement was inde-
pendent of ATP hydrolysis as confirmed by using the non-
hydrolysable ATP-PNP (data not shown). Moreover, it could not
be attributable to an increase in the minimal residual proteolytic
activity of IDEQ (Figure S2). To further characterize the products
in the presence of ATP, these were visualized by TEM at steady
state. A homogeneous population of protofibrils of ,10 nm was
seen in the Ab samples co-incubated with IDEQ and ATP in
contrast to the typical amyloid fibrils formed by Ab alone
(Figure 4). The incubation of IDEQ and Ab at a 1:1 stoichiometry
did not yield a lower absorbance than IDEQ-Ab at 1:10 with ATP
(data not shown). However, this result was not unexpected in light
of the rather large aggregates seen under TEM.
IDEQ cannot dissociate Ab fibrils and Ab aggregates
formed in its presence are incompetent for seeding
Ab1-42 was incubated alone for 48 h and then fresh IDEQ was
added at a 1:10 molar ratio. Turbidity measurements after IDEQ
addition were similar to those of Ab1-42 alone, suggesting that no
disaggregation took place and that IDEQ was not capable of
dissociating amyloid fibrils (Figure 4). We next addressed whether
Ab aggregates formed in the presence of IDEQ were competent to
seed the self-assembly of monomeric Ab. An aliquot of Ab1-42
aggregated in the presence of IDEQ (at 1:10 molar ratio,
enzyme:peptide) was taken at steady state, sonicated and added
to a fresh Ab1-42 solution. As expected, seeds obtained by
Figure 3. Time-course of Ab self-assembly assessed by DLS and TEM in presence or absence of IDEQ. (A) Dynamic light scattering (DLS)
time-course of Ab1-42 incubated alone or in the presence of IDEQ, as indicated. White, gray and black areas correspond to ‘‘dead time’’, 48 h and
160 h of incubation, respectively. Arrows indicate Ab species with very high hydrodynamic diameter (DH) (§1000 nm). Ab1-42 was incubated at a 10-
molar excess over IDEQ. Results are representative of three independent experiments. Data were plotted using Sigma Plot 5.3 software to graphically
show the DH (in a logarithmic scale) and the percentage of scattering intensity (I.Scatt) (in a linear scale). (B) Transmission electron microscopy (TEM)
analysis of: Ab1-42 alone showing typical amyloid fibrils (top left); Ab1-42 in the presence of IDEQ (middle left) showing coalescent annular species of
approximately 5–10 nm and the absence of amyloid fibrils. Arrow indicates a large aggregate. Inset, annuli indicated by small arrows; IDEQ alone
(bottom left) forming annular structures of 5–10 nm (inset, large arrows) and thin short rods (inset, thin arrows); Ab1-42 incubated with IDEwt
inhibited with EDTA (top right), showing no amyloid fibril formation. Inset, arrows depict 5–10 nm annuli and rods. Electron micrographs were
obtained after 6.5 days of incubation. Samples incubated for 30 days revealed typical amyloid fibrils for Ab1-42 alone (middle right) in contrast to a
homogeneous population of small annuli of 5–10 nm in the presence of IDEQ (bottom right). In all TEM experiments, molar ratios were 1:10
(enzyme:Ab). Bars in left panel and top and middle right panel = 100 nm, in insets, bars = 20 nm. In bottom right, bar = 30 nm.
doi:10.1371/journal.pone.0059113.g003
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sonication of fibrillar Ab1-42 shortened the lag phase and
increased the light scattering plateau. Strikingly, the ‘‘seeds’’
obtained from the co-incubation of Ab1-42 with IDEQ had no
effect on the aggregation rate when compared with Ab1-42 self-
assembly alone, as shown by the super-imposable scattering curves
in both conditions (Figure 4). When end-products obtained from
steady state were analyzed by TEM, typical amyloid fibrils were
observed in case of Ab1-42 with or without seeds, yet it tended to
be longer in the former (not shown). These results suggest that
IDEQ not only modifies the kinetics of Ab self-assembly but that
non-fibrillar Ab species formed in the presence of IDEQ lack the
ability to act as templates for monomeric Ab to follow the
amyloidogenic pathway.
Differential solubility and secondary structure of Ab
species formed in the presence of IDEQ
To study the effect of IDEQ upon Ab1-42 solubility, samples
were co-incubated for 5 days, centrifuged at low speed and
analyzed by Western blot. Total immunoreactivity of Ab1-42 in
the supernatant was 2-fold higher after incubation with IDEQ as
compared to Ab1-42 alone. Accordingly, a higher proportion of
Ab1-42 partitioned to the pellet in the absence of IDEQ (Figure 5).
Major differences in Ab pellets were accounted for by trimers,
tetramers and high molecular mass SDS-resistant oligomers. To
determine the secondary structure of soluble Ab oligomers formed
alone or in the presence of IDEQ, Ab1-42 was incubated at 1:300
molar ratio (to minimize enzyme signal) and far UV-CD spectra
analyzed. The effect of IDEQ in preventing amyloid fibril
formation at this molar ratio was assessed by TEM (Figure S5).
IDEQ alone showed a spectrum with minima at 208 and 222 nm,
consistent with its reported structure [46]. In contrast, the spectra
of fresh Ab1-42 alone or Ab1-42 with IDEQ were mainly
unstructured, in accordance with the negligible contribution of
signal by IDEQ (Figure 5). After 6 days of incubation, samples
were centrifuged to separate large aggregates and far UV-CD
spectra obtained from the supernatants. Soluble Ab1-42 in the
absence of IDEQ showed a minimum at,213 nm, but the bulk of
the peptide was unstructured with one third of its original
intensity, consistent with the results obtained by Western blots
(Figure 5). Notably, Ab1-42-IDEQ spectrum was at least 2-fold
more intense than Ab1-42 alone displaying minima at 208 and
Figure 4. Effect of IDEQ and ATP upon the kinetic of Ab aggregation and seeding. (A) Turbidity profiles of Ab1-42 at 15 mM alone in
working buffer (m) or in the presence of IDEQ at the indicated molar ratios (IDEQ:Ab), from top to bottom: 1:200 (%), 1:100 (D), 1:10 (q) and 1:10
containing 0.5 mM ATP (N). Light scattering at 340 nm was measured every 30 min using a TECAN GENios multi-well reader (for clarity, only the
points every other 90 min are shown). The bracket encloses the curves obtained after co-incubation of Ab1-42 with IDEQ at the indicated conditions.
Results are expressed as mean 6 S.E.M. of at least two independent experiments in duplicate. (B) Representative TEM images of samples at steady
state of Ab1-42 alone (top) or with IDEQ at 1:10 molar ratio in the presence of ATP (bottom). Bars = 100 nm. (C) Time course of Ab1-42 aggregation
alone (m), in the presence of seeds previously formed with IDEQ (q), or after the addition of pure Ab1-42 seeds (%). (D) Kinetics of aggregation of
Ab1-42 after the addition of IDEQ (q) or the same volume of working buffer (m) to Ab1-42 after 48 h of self-assembly, as indicated by the arrow.
doi:10.1371/journal.pone.0059113.g004
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214 nm. These results suggest that soluble Ab1-42 species formed
in the presence of IDEQ, either bound or unbound to the enzyme,
were more structured than soluble Ab1-42 incubated without
IDEQ.
Ab1-42 aggregates formed in the presence of IDEQ are
not neurotoxic
The Ab aggregates seen by DLS and TEM together with the
CD data raised the possibility that co-incubation with IDEQ
resulted in the generation of toxic Ab non-fibrillar species. When
Ab was incubated alone for 4 days, mainly spherical oligomers,
rods and protofibrils were seen under atomic force microscopy
(AFM) (Figure 6). In the presence of IDEQ, aggregates were more
heterogeneous and slightly larger as compared to Ab alone
(Figure 6). Primary neurons exposed to Ab1-42 aggregates showed
a remarkable retraction and nicking of their processes and a
,40% reduction in viability. In contrast, cells exposed to Ab1-42
aggregates obtained from co-incubation with IDEQ had no
morphological alterations and were ,95% viable as compared
with control cells (Figure 6). Co-incubation of Ab1-42 with BSA
showed a trend toward lower toxicity although it was not
statistically different from that induced by Ab1-42. To rule out a
possible trophic effect upon neuronal viability of IDEQ unrelated
to its effect on Ab1-42 aggregation, cells were exposed to IDEQ
alone and showed no significant differences with vehicle treatment.
Discussion
The catalytically inactive IDEQ was capable of forming a highly
stable complex with Ab1-42 more efficiently than IDEwt. In
agreement with our prior work using IDEwt, competition with
insulin suggested that at least part of the substrate binding site was
involved [44]. IDEQ-AbSCx was generated in a broad range of
pH, including that compatible with cellular secretory and
endocytic vesicles in which both IDE and Ab are present in vivo
[49,54]. These properties of IDEQ suggested another inherent
function of IDEwt unrelated to hydrolysis. Purified IDEwt
aggregates at pH,6 after long incubation times required for full
Ab self-assembly and retains a ,10% of activity. Thus, to rule out
hydrolysis-dependent effects we used the inactive mutant IDEQ. It
Figure 5. Effect of IDEQ upon solubility and secondary structure of Ab aggregates. (A) samples containing Ab1-42 before incubation
(‘‘dead time’’) and after incubation for 5 days with or without IDEQ were centrifuged at 3,0006g for 5 min and supernatants and pellets analyzed by
Western blots with anti-Ab 6E10 and 4G8. Arrowheads indicate: H, high molecular mass oligomers, T, Ab tetramers and t, Ab trimers. (B)
Densitometric quantification of Ab1-42 obtained from Western blots shown in panel (A). Bars represent the mean 6 SEM of total Ab
immunoreactivity in arbitrary units (AU). * p,0.05, Student’s t test. (C) Far UV-CD spectra recorded at ‘‘dead time’’ of Ab1-42 (solid black line), IDEQ
alone (dotted line) and Ab1-42 co-incubated with IDEQ (solid gray line) at a 1:300 molar ratio (IDEQ:Ab). (D) Far UV-spectra recorded after 6 days of
incubation of Ab1-42 alone or Ab1-42 with IDEQ at 1:300 molar ratio. Samples were centrifuged as described above and supernatants analyzed. IDEQ
alone, dotted line; Ab1-42 alone, solid black line; Ab1-42 co-incubated with IDEQ, solid gray line.
doi:10.1371/journal.pone.0059113.g005
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is important to remark that the ELISA assay is not capable of
detecting Ab in a stable complex with IDEQ. Therefore, the
residual activity of IDEQ (,6%) as determined by this method, is
likely overestimated.
Figure 6. Ab1-42 oligomers formed in the presence of IDEQ are not neurotoxic. (A) Representative AFM images showing the size and
morphology of Ab1-42 neurotoxic species. Left, Ab1-42 incubated alone for 4 days. Approximately spherical species of ,20–30 nm are indicated by
arrowheads. Rods and short protofibrils are depicted by arrows. Inset: a larger Ab1-42 protofibril is shown. Right; Ab1-42 incubated in the presence of
IDEQ at a 1:10 molar ratio (IDEQ: Ab) showing larger aggregates of 50–60 nm (arrowheads) and rods with lengths of ,100–120 nm (arrows). (B)
Representative immunofluorescence of primary differentiated neurons exposed to vehicle, Ab1-42 alone or Ab1-42 pre-incubated with IDEQ from top
to bottom, as indicated. White arrows point at neuronal processes. Bars = 30 mM. (C) Analysis of neuronal processes under the conditions as shown in
panel (A). Bars represent the mean6 SEM of processes’ lengths as measured from the centre of the neuronal body * p,0.01, one-way ANOVA, Tukey
post-hoc test. (D) Viability of mature primary neurons after the indicated treatments as assessed by MTT reduction. * p,0.05, one-way ANOVA, Tukey
post-hoc test. Results are shown for three independent experiments.
doi:10.1371/journal.pone.0059113.g006
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At neutral pH, the size and morphology of Ab aggregates were
drastically modified by IDEQ. Ab aggregates were smaller and did
not form amyloid fibrils in the presence of IDEQ, as shown by
DLS and TEM. Instead, small annuli, rods and protofibrils were
found, even after 30 days of co-incubation, ruling out retardation
or a purely kinetic effect upon Ab self-assembly. The time-course
of turbidity experiments showed that 1) IDEQ at substoichiometry
down to 1:200 was sufficient to slow down the lag and exponential
phases with a lower turbidity at steady-state; 2) the addition of
IDEQ at the end of the exponential growth phase was ineffective
to prevent amyloid formation or to modify its kinetics; 3) sonicated
end-products of Ab-IDEQ co-incubation were incompetent to
induce the ‘‘seeding’’ of Ab monomers, indicating that they did
not form amyloidogenic templates. These results are consistent
with IDEQ exerting its effect at early stages of Ab aggregation,
most likely before the exponential phase of amyloid fibril
elongation. Interestingly, the presence of ATP at its kd enhanced
the anti-amyloidogenic effect of IDEQ. This effect was indepen-
dent of ATP hydrolysis and may be related with the reported
stimulation of the catalytic activity of IDEwt upon very short
peptide substrates by polyphosphate anions (see below). Western
blots of insoluble and soluble aggregates showed a 2-fold increase
of Ab species in the supernatant in the presence of IDEQ,
including intermediate and high molecular mass SDS-resistant
oligomers with a likely content of b structure. The potential
neurotoxicity of these Ab oligomers and aggregates was ruled out
by the exposure of primary neuronal cultures in which Ab, in the
presence of IDEQ, yielded non-toxic species as assessed by
neuronal viability and morphology.
Regarding the possible mechanism underlying the anti-amyloi-
dogenic effect of IDEQ, we propose that it relies on a chaperone-
like activity. Similar effects upon Ab aggregation have been
described for Hsps 70/40, Hsp90, Hsp104 and small heat shock
proteins (sHsp20) [30,31,55]. These effects include the blockage of
the amyloid pathway resulting in non-fibrillar aggregates, the
competence at substoichiometry, and their activity at early stages
of the aggregation process, except for Hsp104 which shows activity
at different stages [55]. In some cases, Ab oligomers formed in the
presence of chaperones have been proven to be non-toxic to
neuronal cell lines [31].
The three-dimensional structure of IDEQ crystallized with
several substrates [46] including insulin and Ab1-40 displays
features that are relevant to the interpretation of our findings: 1)
the presence of a chamber that has the approximate volume of a
native insulin monomer, enclosed by the amino-terminal half
(domains 1 and 2) and the carboxyl-terminal half (domains 3 and
4); 2) the existence of a substrate binding ‘‘exosite’’ (,30 A˚ away
from the catalytic residues) that contributes to guide the partial
unfolding of substrates; 3) the stabilization of short b strands
common to all substrates (not present in the free state in solution)
at the ‘‘exosite’’ and at the catalytic site; 4) the alternation between
closed and open states of the IDE chamber articulated upon a
flexible loop connecting IDE halves which may be the rate limiting
step for the catalytic cycle; 5) an inner acidic surface of domains 3
and 4 that contributes to stabilize the ‘‘closed’’ conformation in the
absence of substrate and 6) the relatively slow Kcat (in the order of
min 21) for amyloidogenic peptides [56,57].
Our initial observation of an IDEQ-Ab highly stable complex
with an apparent 1:1 stoichiometry (after SDS treatment) and
occupying at least part of the binding sites led us to speculate that
after binding, a population of Ab alone or together with a partner
sequence on IDE may provide a template for additional binding of
Ab monomers or small oligomers. IDE-Ab complexes may then
progress to form non-amyloid aggregates. Although the closed
IDEQ chamber may be limiting in this mechanism, the binding of
at least another Ab monomer would impose a steric hindrance for
‘‘IDE closure’’, facilitating the assembly process upon the IDEQ-
Ab template. The major polyanion binding site has been recently
proposed by crystallographic analysis to be located at a positively
charged inner surface contributed by IDE domains 3 and 4 [53].
The enhancement of the anti-amyloidogenic effect by ATP may
be related with a reduced electrostatic attraction between IDE
halves, favoring the open state and the aggregation of Ab upon
IDEQ-Ab templates. We propose that such aggregation takes
place much faster (,30 min) than the lag phase of amyloidogenic
Ab self-assembly and lowers free monomer concentration, a
limiting factor for nuclei formation.
Although insulin is non-amyloidogenic under physiological
conditions, the high affinity between IDE and insulin, the assisted
partial unfolding of insulin inside the IDE chamber and the lack of
proteolysis by IDEQ, raised the question whether IDEQ could
induce stable insulin conformational changes and/or self-aggre-
gation. Notably, despite a long co-incubation, IDEQ had no effect
upon insulin conformation as assessed by CD and receptor
activation on cultured cells.
Taken together, these results are consistent with IDEQ having a
chaperone-like activity upon Ab aggregation with a holdase or
mixed (‘‘foldase-holdase’’) type of mechanism. Proteases and
chaperones share the capability of binding partially folded or
unfolded polypeptides. Both activities have been extensively
studied in proteins of the C1pP, FtsH and Lon families; highly
conserved ATP-dependent proteases with chaperone activity
[58,59]. Proteases in which the catalytic site is required for a
chaperone-like activity include the aspartic proteases pepsin and
HIV protease, as shown by following the aggregation of denatured
citrate synthase or rhodanese [60]. In the same work, thermolysin -
a typical M13 Zn2+ metallopeptidase- did not show chaperone
activity but this remains to be tested with relatively short peptides
such as Ab. In gram-negative bacteria, the IDE ortholog, pitrilysin
(PTR) is targeted to the periplasmic space in which it is believed to
degrade small peptides derived from leader sequences [61]. In
eukaryotes, IDE has been found in cytosol, plasma membrane,
endocytic pathway, mitochondria, exosomes and extracellular
space [42]. Several cellular factors may impact upon IDE
proteolytic activity. Acidic pH, oxygen reactive species, oxidized
glutathione and nitric oxide can reduce the catalytic function of
IDE [62,63]. Moreover, it has been shown that naturally occurring
IDE missense mutations in a rat model of DM2 reduce IDE
proteolytic activity upon insulin and Ab [64]. Therefore, under
physiological (low pH in endocytic and exocytic vesicles) or
pathological conditions (oxidative stress, inflammation, mutations),
a latent chaperone activity of IDE may become relevant to prevent
Ab toxic aggregation.
The M16 family members presequence protease (PreP) in
chloroplasts and human metalloprotease 1 (MP1) in mitochondria
are capable of degrading Ab [65,66,67]. PreP crystal structure and
its proposed mechanism of recognition and catalysis are similar to
those of PTR and IDE, including a ‘‘peptidasome’’ chamber that
encloses peptide substrates [68]. A chaperone-like activity of IDE
and related M16 proteases such as PTR or PreP and MP1 under
suboptimal conditions for hydrolysis may enhance their efficiency
in preventing the self-assembly of small peptides into toxic
oligomers. By driving the formation of non-toxic and more soluble
aggregates, such activity may facilitate their cellular disposal by
general degradation systems.
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Materials and Methods
Site-directed mutagenesis
Rat IDE cDNA 42–1059 was kindly provided by Dr. Richard
Roth, Stanford University). The Glu by Gln substitution at
position 111 was introduced by PCR using the forward primer:
59CCTGGCTTAAGCCATTTTTGTCAGCATATGCTGTT-
TTTGGGAACA39 and the complementary reverse primer. After
cloning in plasmid pET 30 a (+) (Novagen), whole plasmid was
amplified and the PCR product treated with Dnp I. Digestion of
the methylated or hemi-methylated DNA template allowed the
selection of the mutation-containing DNA. To confirm that the
desired mutation was correctly introduced, the IDE insert was
sequenced using a primer for the T7 promoter.
Expression and purification of IDEwt and IDEQ
IDEwt and IDEQ were expressed in E. coli BL21 transformed
with pET 30 a (+) vector containing the corresponding cDNAs.
Bacteria were cultured in TB medium containing 100 mg/mL
kanamicin at 37uC and protein expression induced with 0.5 mM
isopropyl-b-D- 1-thiogalactopyranoside (IPTG). The first purifi-
cation step was done with a His-Trap Ni2+ affinity chromatogra-
phy (GE Healthcare) in 50 mM Tris-HCl, pH 8.0, 300 mM NaCl
followed by elution with a linear gradient from 20 to 250 mM
imidazole in the same buffer. The second purification step was
size-exclusion chromatography (SEC) with a Superdex 200
columm (Amersham) in 50 mM NaCl, 20 mM Tris-HCl,
pH 7.4 (working buffer). After SEC, protein purity was deter-
mined by SDS-PAGE and quantified by measuring absorbance at
280 nm using the IDE extinction coefficient (115810 M21 cm21).
Concentration was expressed as monomeric IDE.
Ab peptides preparation and IDE-AbSCx formation
Ab1-40 (Sigma) and Ab1-42 (American Peptide Co) were
acquired as lyophilized powder. Ab1-28Q was kindly provided by
Jorge Ghiso (New York University). Peptides were first dissolved in
1,1,1,3,3,3-hexa-fluoro-2-propanol (HFIP) at 1 mg/ml, incubated
at room temperature for 8 h and stored at 280uC until use. To
disaggregate possible Ab nuclei, prior to each experiment an
aliquot was taken from the stock solution and sonicated for 10 min
on ice. After removing HFIP with gentle streaming of nitrogen,
peptides were dissolved in working buffer and sonicated for
10 min on ice. Finally, peptides were centrifuged for 30 min at
10,0006 g to pellet insoluble material and the supernatants
filtered through 0.22 mm spin filters (Sigma). To obtain IDEwt or
IDEQ AbSCx, purified enzymes and peptide were incubated at
1 mM and 35 mM, respectively, in working buffer at 25uC for the
indicated times. At the end of incubation, samples were analyzed
by Western blots as described below. Data were fitted to a single
exponential equation to calculate half-lives as described [44].
IDE activity assays
IDEwt and IDEQ enzymatic activities were assessed by four
different methods. 1) Hydrolysis of the fluorogenic peptide 7-
methoxycoumarin-RPPGFSAFK-2, 4-dinitrophenyl (‘‘substrate
V’’, R&D Systems) containing the bradykinin sequence. The
enzymatic activity of IDEwt (10 nM) was determined using
increasing concentrations of substrate V in working buffer,
pH 7, for 10 min at 37uC. The sigmoidal plot of V0 as a function
of substrate concentration allowed us to calculate a K0.5
,12.5 mM. To compare the activities of IDEwt and IDEQ,
proteins were incubated at 10 nM with substrate V at 10 mM in
working buffer at 37uC for up to 10 min. The increase in
fluorescence was monitored with an Aminco-Bowman spectroflu-
orometer at 320 nm and 405 nm as excitation and emission
wavelengths, respectively. 2) TCA precipitation of porcine insulin
degradation. Briefly, 20,000 cpm of 125I-insulin (specific activity
300 mCi/mg, kindly provided by Edgardo Poskus, University of
Buenos Aires) were incubated for 30 min at 37uC in working
buffer containing 0.25% BSA and 10 ng of IDEwt or IDEQ. ATP
was added at 0.5 mM to IDEQ, as indicated. The reaction was
stopped by addition of 0.1 ml of 15% TCA. Samples were
centrifuged at 12,0006 g for 30 min at 4uC and c.p.m.
determined in pellets and supernatants using an automatic
gamma-counter. 3) Western blots after incubation of Ab1-42 with
or without IDEQ were performed as described below. 4) ELISA
quantification was performed on samples with Ab1-42 (15 mM)
alone or in the presence of IDEwt, IDEwt containing 5 mM
EDTA or IDEQ at 1:10 molar ratios (enzymes: peptides). At
‘‘dead-time’’ or after 5 days of incubation at room temperature,
aliquots of 2 ml were mixed with 2 ml of distilled water and 1 ml of
5M guanidine-HCl in water. Ab42 levels were quantified by using
a commercial ELISA kit following the manufacturer’s instructions
(Invitrogen).
IDEwt activity assays in pH range 5.5 to 7.5
The effect of pH on IDEwt activity was determined in a pH
range from 5.5 to 7.5 using the fluorogenic peptide substrate V as
described above. One hundred mM citric acid or 100 mM
PO4NaH2/ PO4Na2H were used to reach the specified pH in
each case.
Circular dichroism and thermal denaturation of IDEwt
and IDEQ
Far UV-CD spectra measurements were carried out in a Jasco
J-815 spectropolarimeter equipped with a Peltier temperature-
controlled sample holder device. Spectra of IDEwt or IDEQ at
0.5 mM in working buffer at 25uC were acquired before and after
thermal denaturation at 1uC/min using a 0.2 cm path length
quartz cuvette. Final spectra were obtained after the subtraction of
background readings of working buffer. Thermal denaturation was
followed by plotting the signal at 222 nm.
Static light scattering assays (SLS)
The average molecular masses of IDEwt or IDE-Q were
determined with a Precision Detector PD2010 light scattering
instrument. Briefly, 200 mg of a purified batch of IDEwt or IDEQ
were injected into a Superdex G-200 column (Amersham)
connected to an HPLC system Bromma LKB 2248 and eluted
in working buffer at 0.5 ml/min. To estimate the average
molecular mass of proteins, the 90u static light scattering signal
and UV absorbance or refractive index of the eluting material
were recorded and analyzed with the Discovery 32 software
(Precision Detectors). The 90u light scattering detector was
calibrated using bovine serum albumin (66.5 kDa) as a standard.
Average values obtained from four independent measurements of
the apparent molecular masses of IDE dimers and tetramers were
,250 and ,500 kDa, respectively.
Dynamic light scattering (DLS)
Ab monomeric species, obtained as described above, were
incubated at 50 mM in working buffer at 25uC for the indicated
times with or without IDEQ at a molar ratio 1:10 (enzyme:pep-
tide). The same molar ratio was used for BSA as a control for
specificity. Particle size measurement was assessed using the
633 nm excitation laser and detector at 173u with a Zetasizer
Nano-S (Malvern Instruments). Results were expressed as the
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intensity of scattered light as a function of DH and time of
incubation.
Transmission electron microscopy (TEM)
Aliquots were taken from the same samples used for DLS
measurements or from samples at steady state of turbidity
experiments (see below). Ten ml were adsorbed for 1 min onto
formvar-coated nickel grids (Electron Microscopy Science) and
stained with 1% uranyl acetate aqueous solution for 1 min. Grids
were visualized on a Zeiss 10C Transmission Electron Microscope.
Turbidity assessment of Ab aggregation kinetics and
seeding
One hundred and fifty ml of Ab1-42 at 10 mM were loaded per
well in a 96-multiwell polystyrene plate with flat bottoms (Nunc).
Co-incubation with IDEQ was done at the indicated molar ratios.
Plates were placed in a TECAN Genios multi-well reader and
peptide aggregation followed by measuring absorbance at 340 nm
every 30 min with a 10-s mixing shake before each measure. Pre-
formed seeds were obtained from samples at steady state by
sonication for 5 min on ice. The seeding assay was carried out by
adding 1% v/v of seeds to a fresh preparation of monomeric Ab.
All experiments were performed at constant 25uC.
AFM characterization of non-fibrillar Ab1-42 species
Aliquots of Ab1-42 or Ab1-42 with IDEQ were collected after 4
and 6 days of incubation, deposited onto freshly cleaved mica and
left for 1 min at room temperature. The specimens were then
rinsed with deionized water and dried with a nitrogen stream (1
bar). Images were collected after dynamic scanning force
microscopy in air by using a Veeco Explorer AFM fitted with a
tube-type 2 micrometer scanner and antimony doped silicon
cantilever tips (spring constant 1–5 N/m; Veeco). Tapping/Non-
contact mode using a FESP-MT tip and a gain of 2.0 V were used.
Three sample regions covering 4 mm2 were randomly documented
and 100 to 1500 elements from each region were analyzed.
Particles’ heights, widths and lengths were measured by using the
Nanotec WSxM 4.0 Image Browser software.
CD assessment of Ab and insulin-IDEQ co-incubation
Ab1-42 at 15 mM in working buffer alone or in the presence of
IDEQ at 1:300 molar ratio (enzyme:peptide) were incubated for
6 days at 25uC. Spectra were acquired at dead-time and at the end
of incubation over a wavelength range of 260–202 nm using a
Jasco J-815 spectropolarimeter in 10-mm path cuvettes. Data
interval was set at 0.2 nm and the average of five scans was
obtained for each experimental conditions. Insulin secondary
structure was determined in the presence or absence of IDEQ at a
1:100 molar ratio (enzyme:peptide) incubated for 24 h at 25uC. In
both experiments, UV-CD spectra were smoothed with an
algorithm provided by JASCO after the subtraction of working
buffer background signal.
SDS-PAGE and Western Blots
Proteins were subjected to electrophoresis on 7.5 or 10%
polyacrylamide SDS-Tris-tricine gels, stained with Coomassie blue
or transferred to PVDF membranes (GE Healthcare). For Western
blots, membranes were blocked with 5% low fat milk in PBS
containing 0.1% Tween for 2 h at room temperature and
incubated with the indicated primary antibodies overnight at
4uC. Anti-Ab monoclonal 6E10 and 4G8 were obtained from
Signet. Anti-rabbit or anti-mouse horseradish peroxidase-labeled
antibodies were used for detection using ECL Plus reagent
(Amersham Biosciences). Enhanced chemiluminescence signals
were scanned with a STORM 860 fluorometer and analyzed with
ImageQuant 5.1 software (Molecular Dynamics). To quantify
IDE-AbSCx formation, the amount of total IDE in each lane was
estimated by Coomassie blue staining of the same PVDF
membranes used for fluorescence detection.
Primary neuronal cultures
Neuronal cultures were obtained from rat embryos as described
[69]. Briefly, hippocampi were dissected free of meninges,
suspended in 0.5 ml of Ca2+ and Mg2+ – free Hank’s balanced
solution and treated with 0.25% trypsin (Invitrogen) for 25 min at
37uC. Immediately after trypsinization, tissue was washed with
Neurobasal medium (Gibco) containing 10% fetal bovine serum
supplemented with B-27 and N-2, 50 U/ml penicillin and 50 mg/
ml streptomycin (NBSM). A cellular suspension was obtained by
using fire-polished Pasteur pipettes. For immunofluorescence,
isolated cells were plated at 60/mm2 on 12-mm coverslips. For
viability assessment, cells were plated at 36104 on P-96 wells. After
3 h of incubation under 5% CO2 at 37uC to permit cell
attachment, medium was replaced with fresh medium without
serum. Neuronal cultures with a purity of 90–95% were obtained.
Cultures were maintained in NBSM without serum for 14 days to
allow neuronal differentiation.
Inmunofluorescence and neurotoxicity assay
To assess neuronal damage induced by Ab1-42, cells were
examined by immunofluorescence (IF). The remaining viability
was determined using an (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. Neurons were exposed for
20 h to 10 mM Ab1-42 in NBS, washed with PBS and fixed with
4% paraformaldehyde. For immunofluorescence, cells were
permeabilized with 0.1% Triton X-100 in PBS and blocked with
PBS containing 0.1% BSA. To recognize specifically neuronal
morphology, anti-b III tubulin monoclonal IgG (Sigma) was
incubated for 1 h, followed by Cy3-labeled goat anti-mouse IgG.
Nuclei were labelled with the blue-fluorescent Hoechst acid stain.
Images were captured using an Olympus BX60 microscope with a
DP Controler 3.1.1.267 PC program. The average length of
neuronal processes was determined using Image J software.
Quantitative estimation of remaining cellular viability was assessed
by the reduction of MTT by mitochondria of living cells. MTT
was incubated at 0.5 mg/ml for 2 h at 37uC and products of
reaction dissolved in 0.1N HCl and 2% SDS in water. Absorbance
was measured at 570 nm and viability expressed as the O.D.
relative to neurons treated with vehicle alone. As a positive control
for neuronal damage, cells were exposed to 0.05% H2O2 (not
shown). Quantitative data of three independent MTT assays were
analyzed by one-way ANOVA and a post-hoc Tukey test with
Graph Pad Prism v. 4.0. All results represent the mean 6 SEM
and p,0.05 was considered statistically significant.
Insulin receptor activation assay
Human glioma U-87 cells (ATCC HBT-14) were cultured at
37uC with 5% CO2 in DMEM high glucose media supplemented
with non-essential amino acids (PPA) and 2 mM piruvic acid. Cells
at 80% confluence were deprived of serum for 24 h and exposed
to 100 nM insulin for 30 min. Insulin was co-incubated with
IDEQ or IDEwt for 24 h at 25uC before cellular exposure. After
treatments, cells were washed with cold PBS, harvested and lysed
by passage through a 25-gauge needle 20 times in 150 mM
PO4H2Na, pH 7.5 containing 150 mM NaCl, 0.5% deoxycholic
acid, 1% Triton X-100 and a cocktail of protease inhibitors
(Sigma). Homogenates were centrifuged for 10 min at 12,0006 g
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and protein concentration in the supernatant determined with a
Pierce BCA kit. To detect Akt and phosphorylated Akt at Ser 473
under different conditions, 65 mg of total protein were separated
on 10% SDS-PAGE and transferred to PDVF membranes.
Polyclonal rabbit anti-Akt and monoclonal mouse anti-p-Akt
antibodies from Cell Signaling were used for Western blots. To
assess the specificity of signaling, phophatidyl-inositol-3 kinase
(PI3K) was inhibited by incubating cells with 100 nM wortmannin
(Millipore) for 30 min prior to insulin exposure.
Ethics Statement
The protocol for the care, handling and use of animals followed
the ARRIVE guidelines [70] and was approved by the Fundacio´n
Instituto Leloir Institutional Animal Care and Use Committee.
Supporting Information
Figure S1 Purity and conformation of IDEQ. (A) Coo-
massie blue staining of a 7.5% SDS-PAGE showing the purity of
recombinant IDEwt and IDEQ obtained from SEC. Two mg of
IDEwt or IDEQ were loaded in each lane. On the left, molecular
mass markers are indicated in kilodaltons (kDa). (B) Thermal
denaturation of IDEwt (q) and IDEQ (N) at 0.8 mM was assessed
by monitoring signal loss at 222 nm as a function of increasing
temperature. Proteins were incubated in working buffer (20 mM
Tris-HCl, pH 7.4, containing 50 mM NaCl) at 37uC for 5 min
before the initiation of a temperature increase from 25uC to 85uC
at 1uC per min. Inset, far UV CD spectra of proteins before
(IDEQ, black solid line; IDEwt, gray solid line) or after thermal
denaturation (IDEQ, black dotted line; IDEwt, gray dotted line).
(C) Elution profiles obtained for IDEwt and IDEQ after SEC with
a Sephadex G-200 column showing the molecular masses of native
IDEwt and IDEQ dimers (D), solid arrows) and tetramers (T),
dashed arrows) by SLS arranged in a flow-cell fashion.
(TIF)
Figure S2 Loss of proteolytic activity of IDEQ. (A) IDEwt
initial velocity of degradation (V0) as a function of substrate V
concentration. K50 = 12.5 mM. (B) Time course of the hydrolysis
of fluorogenic substrate V at 10 mM in the presence of IDEwt (q)
or IDEQ (%). Fluorescence in the absence of IDE (buffer alone) is
depicted by (X). (C) IDE activity as assessed by insulin
degradation. 125I-insulin was incubated for 30 min at 37uC in
working buffer containing 0.25% BSA and 10 ng IDEwt or IDEQ
(with or without ATP) followed by precipitation with trichlor-
oacetic acid (TCA). Results are expressed as 125I-insulin remaining
in the pellets. Bars represent the mean6 SEM of two independent
experiments performed in duplicate. (D) Top, representative
Western blot showing the lack of degradation of Ab1-42 by IDEQ
in the presence of 0.5 mM ATP. Ab1-42 was incubated alone or
with IDEQ (1:10 molar ratio, enzyme:Ab) at 25uC for 2 h and
separated on a 10% SDS-PAGE. Bottom, Coomassie blue staining
of the same membrane used for Western blot showing IDEQ
(arrow). (E) ELISA measurement of Ab1-42 after 5 days of
incubation with, IDEQ, IDEwt or IDEwt in the presence of
EDTA, as indicated. Results are expressed as the percentage of
monomeric Ab1-42 referred to Ab levels in non-incubated samples
as 100%. Bars represent the mean 6 SEM of two independent
experiments. In all cases, molar ratios were 1:10 (enzymes:Ab).
(TIF)
Figure S3 Activity and IDE-AbSCx formation as a
function of pH. (A) IDEwt activity was measured using substrate
V at 10 mM for 5 min at 37uC and expressed as the percentage of
activity relative to pH 7.5. Bars represent the mean 6 SEM of
three independent measurements. (B) Top, IDEwt-AbSCx
formation (arrowhead) as determined by Western blot with
6E10. The same membrane was stained with Coomassie blue to
control for IDEwt loading, as shown below the Western blot.
Bottom, densitometric quantification. Bars represent the mean 6
SEM in arbitrary units (A.U.) of IDE-AbSCx immunoreactivity.
(TIF)
Figure S4 TEM analysis of the effect of IDEQ upon
amyloid formation by Ab28Q. (A) Ab28Q alone showing
typical amyloid fibrils. (B) Ab28Q co-incubated with IDEQ
showing large coalescent aggregates (arrow) of annular structures
of less than 10 nm (inset, large arrow) and short protofibrils (thin
arrow). (C) Ab28Q incubated with BSA showing the formation of
amyloid fibrils. Bars = 100 nm; insets, bars = 20 nm; H,
bar = 30 nm.
(TIF)
Figure S5 TEM analysis of the IDEQ-Ab preparation
used for CD measurements. (A) Ab1-42 after 6 days of
incubation showing typical amyloid fibrils. Bar = 100 nm. (B) Ab1-
42 incubated with IDEQ at a 1:300 molar ratio (enzyme: Ab) for
6 days. Short arrows indicate annuli or 5–10 nm, long arrows
indicate short rods or protofibrils ,5 nm wide and 15–30 nm
long. Bar = 30 nm.
(TIF)
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